title: Chemotherapy of disseminated Merkel-cell carcinoma.
abstract: Six patients developed metastatic merkel-cell carcinoma and were treated with a combination chemotherapy frequently used for small-cell lung cancer. Five of six patients had a complete response for a median of 3.5 months. Overall survival from initiation of chemotherapy was a median of 6.5 months. Two patients died from major complications of therapy.
authors.affiliation: Hematology-Oncology Service, Walter Reed Army Medical Center, Washington D.C.
authors.forename: J
authors.initials: J
authors.lastname: Redmond
authors.forename: J
authors.initials: J
authors.lastname: Perry
authors.forename: P
authors.initials: P
authors.lastname: Sowray
authors.forename: S J
authors.initials: SJ
authors.lastname: Vukelja
authors.forename: N
authors.initials: N
authors.lastname: Dawson
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015266:Carcinoma, Merkel Cell / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D012074:Remission Induction / Q000379:methods; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin